Andrew Nicholson is head of diagnostic thoracic pathology at the Royal Brompton Hospital and Honorary Professor of Respiratory Pathology, National Heart and Lung Institute, Imperial College London.
Professor Andrew Nicholson trained at Oxford University and then St Bartholomew’s Hospital, London. He lectures regularly at international conferences, and has co-organised several international meetings.
He is a member of the International Association for the Study of Lung Cancer (IASLC) pathology panel, membership committee and staging committee. He is specialist advisor to the Royal College of Pathologists for lung cancer and a member of the Department of Health Advisory Group for lung cancer and mesothelioma. He is General Secretary for the British Division of the International Academy of Pathologists.
He has co-authored over 200 publications, predominantly on interstitial lung disease and cancer (lung and mesothelioma), being involved in several committees internationally producing guidelines for the management of idiopathic pulmonary fibrosis and lung cancer. He also wrote sections for the most recent WHO classification of lung tumours. He has co-authored Pathology of the Lung, 2nd Edition (3rd now in press), which won first prize in the basic and clinical sciences section of the BMA book awards in 2006, and is currently co-writing the Armed Forces Institute of Pathology fascicle on lung tumours.
et al., 2022, CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort, American Journal of Respiratory and Critical Care Medicine, Vol:205, ISSN:1073-449X, Pages:1440-1448
et al., 2022, The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors., J Thorac Oncol, Vol:17, Pages:838-851
et al., 2022, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, American Journal of Respiratory and Critical Care Medicine, Vol:205, ISSN:1073-449X, Pages:E18-E47
et al., 2022, Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)- related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management, Cancer Treatment Reviews, Vol:106, ISSN:0305-7372
et al., 2022, The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification, Journal of Thoracic Oncology, Vol:17, ISSN:1556-0864, Pages:608-622